6533b85bfe1ef96bd12bad07
RESEARCH PRODUCT
Bempedoic acid as adjunct for traditional lipid-lowering therapy in patients with hyperlipidaemia
Giulia CancellieriVincenzo SucatoChiara SchimmentiGiuseppina NovoFrancesca MortillaroFabio VenturellaAlfredo R. GalassiElvira Manzonesubject
bempedoic acidmedicine.medical_specialtyStatinmedicine.drug_classHyperlipidemiasFamilial hypercholesterolemia030204 cardiovascular system & hematologyLipid-lowering therapystatins03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineHumansDicarboxylic AcidsIn patient030212 general & internal medicineHypolipidemic AgentsClinical Trials as Topiclipid-lowering therapyCholesterolbusiness.industryFatty Acidsnutritional and metabolic diseasesCholesterol LDLGeneral Medicinemedicine.diseaselow-density lipoproteinchemistryDrug Therapy Combinationlipids (amino acids peptides and proteins)Statin therapyHydroxymethylglutaryl-CoA Reductase InhibitorsatherosclerosisCardiology and Cardiovascular MedicinebusinessBempedoic acidLipoproteindescription
Statin therapy has been the cornerstone for the reduction of cholesterol and circulating low-density lipoprotein (LDL) in patients with cardiovascular diseases. However, statin monotherapy has disadvantages attributable to myopathies and to the insufficient cholesterol reduction observed in some patients. There is a need for new well-tolerated therapies for lowering LDL. This review will focus on bempedoic acid in combination with traditional statin therapy or other lipid-lowering agents and its emerging role in LDL-C lowering. Bempedoic acid is also a viable alternative for reducing LDL cholesterol in the treatment of some patients suffering from heterozygous familial hypercholesterolemia.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-11-25 | Coronary Artery Disease |